Development of Novel Preclinical Models of Secondary Resistance to the Pi3kδ Inhibitor Idelalisib in Splenic Marginal Zone Lymphoma (Smzl)

Hematological Oncology - United Kingdom
doi 10.1002/hon.2438_119
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Mechanisms of Secondary Resistance to Idelalisib in Marginal Zone Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Idelalisib and Rituximab in 17p Deletion–Positive Splenic Marginal Zone Lymphoma

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2018English

Multi-Omics Landscape of Splenic Marginal Zone Lymphoma (Smzl) - Interim Analysis of Ielsg46 Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Splenic Marginal Zone Lymphoma

2020English

A Case of Splenic Marginal Zone Lymphoma

Japanese Journal of Gastroenterological Surgery
SurgeryGastroenterology
2008English

Rituximab Alone (R) Versus Rituximab Plus Bendamustine (Br) for Splenic (Smzl) and Nodal Marginal Zone Lymphoma (Nmzl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Recurrent Autoimmune Hemolytic Anemia in Splenic Marginal Zone Lymphoma

Journal of Community Hospital Internal Medicine Perspectives
Internal Medicine
2018English

Primary Splenic Marginal Zone Lymphoma: A Case Report

Pathology
Forensic MedicinePathology
2016English

CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma

ISRN Oncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy